Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 3 1

Status

Completed 4Withdrawn 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × DOXO-EMCH × Clear all
NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02200757 2024-06-25

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Completed
135 enrolled 11 charts
Thoracic

Small Cell Lung Carcinoma

NCT01580397 2024-06-06

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Completed
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01514188 2024-05-29

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

ImmunityBio, Inc.

Phase 2 Completed
126 enrolled 13 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02014844 2024-05-29

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

ImmunityBio, Inc.

Phase 2 Completed
28 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma

NCT00472771 2012-02-09

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

CytRx

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡